

International Clinical Research (Trials) during COVID-19 era:

Should we suspend or continue?



INTRODUCTION

Clinical research is vitally important as it is the foundation to provide evidence to improve patient care. This online symposium is to focus on the effect of COVID-19 pandemic on the global clinical research (trials) setting.

In addition to the COVID-19 research, how clinical research in various fields other than the COVID-19 has been managed will be introduced in this symposium.

WHO SHOULD ATTEND??

Health professionals from our partners within countries, who are involved or willing to be involved in clinical research (trials) from the design to the implementation.

GET CERTIFICATE and DOWNLOADABLE MATERIALS!!

IT'S **FREE**



Zoom link and ID will be sent via email to each registrant



TWO DAYS ONLINE SYMPOSIUM

REGISTRATION LINK

tc oc c ttos t
t c t sc c c pcs l
c oc c toctc
t c t c c p c l



7JW\Yfy

FULL PROGRAM

| Day 1 March 11, 2021 15:25 – 18:40 (6:25 - 9:40 UTC) | Day 2 March 12, 2021 15:25 – 17:55 (6:25-8:55 UTC) |
|---|--|
| 15:25-15:30 OPENING | 15:25-15:30 OPENING |
|  <p>15:30-15:35 Opening Remarks Dr. Norihiro Kokudo, President of National Center for Global Health and Medicine</p> |  <p>15:30 -15:50 Introductory note: Regulatory perspectives for the R&D on COVID19 Mika Togashi Principal Coordinator, Office of International Programs, PMDA, Japan</p> |
|  <p>15:35-15:45 Developing and maintaining an international clinical trial network activity Dr. Tatsuo Iiyama Director of Department of International Trials, NCGM</p> |  <p>15:50 - 16:20 Keynote Speech: Confronting COVID-19 and the next emerging diseases. Dr Wataru Sugiura Director, Center for Clinical Sciences, NCGM</p> |
| <p>15:45-18:35 Session 1: The New normal for Clinical trials Chair: Hamana Mieko (NCGM-DIT); Co-chair: Muchanga Sifa (NCGM-DIT) In this session, the audience will learn how clinical researches have been managed in various therapeutic areas in COVID-19 affected environment. The session will provide the audience with the opportunity to think of how clinical researches are managed under the constraint.</p> | <p>16:20-17:47 Session 2: COVID-19 clinical studies "Learning from front-line health workers" Chair: Muchanga Sifa (NCGM-DIT); Co-chair: Marilang Siburian (NCGM-DIT) This session provides an opportunity to directly learn how actual clinical trials were developed and managed from the specialists who were engaged in Covid-19 patient care at front line and to think of the implication towards the future.</p> |
|  <p>15:45 –16:05 Impact of COVID-19 on Infectious diseases research (trials) Dr. Norio Ohmagari, M.D., M.Sc., Ph.D. Director, Disease Control and Prevention Center, NCGM</p> |  <p>16:20 – 16:40 COVID-19 at Kinshasa University Clinics (CUK): Epidemioclinical profile and mortality predictors Dr. Mandina Ndona Director, Institute for Research in Health Science (IRSS), Senior Coordinator of the COVID-19 Response at the Kinshasa University Clinics , DR Congo</p> |
|  <p>16:05-16:25 Impact of COVID-19 on cancer clinical trials Dr. Kenichi Nakamura Director, National Cancer Center</p> |  <p>16:40 – 17:00 Management of COVID19 patients: The Philippines experience Dr. Jubert Benedicto Chief of Critical Care Units Management Team (CCU-MAT)</p> |
|  <p>16:25-16:45 Clinical trials in resource limited settings: An example of Leishmaniasis East Africa Platform (LEAP) Dr. Monique Wasunna Director, DNDI Africa</p> |  <p>17:00 – 17:20 Management of COVID19 patients: Indonesia clinical study Dr Vivi Lisdawati Director of Research on Infectious and Communicable Diseases, Sulianti Saroso -Infectious Disease Hospital, Indonesia</p> |
|  <p>16:45 – 17:15 Keynote Speech: Impact of the COVID-19 pandemic on the management of the Intensive Care and the battle of implementing treatment for a new and unknown disease. Mehran Monchi Head of Department of Intensive Care Medicine, Melun General Hospital, France</p> |  <p>17:20 –17:40 The experience of clinical research at the NCGM site Dr Sho Saito Clinical Investigator, Disease Control and Prevention Center, NCGM</p> |
|  <p>17:15- 17:35 Clinical Research between Thailand and Japan in orthopedics Dr. Tsuyoshi Murase Division of Medicine, Graduate School of Medicine, Associate Professor, Osaka University</p> |  <p>17:40 –17:47 Young researcher observations on the management of Covid-19 in Bangladesh Tania Tabassum Global Clinical Research Support Group, Department of Medical Innovation, Osaka University Hospital</p> |
|  <p>17:35- 17:55 Collaborative study of Prospective, MULTicenter, Observational StUdy of the PatLenTs with Heart Failure with Preserved Ejection Fraction (PURSUIT HFPEF) between Japan and Cambodia Dr. Daisaku Nakatani Head of Global Clinical Research Support Group, Department of Medical Innovation, Osaka University Hospital</p> | 17:47-17:52 WRAP UP |
|  <p>17:55- 18:15 Malaria elimination during COVID-19 era Professor Srivicha Krudsood Deputy Director, WHO CC for Clinical Management of Malaria, Faculty of Tropical Medicine, Mahidol University</p> | 17:52-17:55 CLOSING NOTE (Masato Ichikawa, NCGM-DIT) |
|  <p>18:15- 18:35 Clinical trials for devices and IVD other than COVID-19 device (malaria) Dr. Shigeyuki Kano Director of the Department of Tropical Medicine and Malaria, NCGM</p> | |
| 18:35-18:40 WRAP UP | |

Contact info

ditcapacitybuilding@hosp.ncgm.go.jp
 Department of International Trials
 Center for Clinical Sciences
 National Center for Global Health and Medicine
 1-21-1, Toyama Shinjuku-ku,
 Tokyo 162-8655 Japan
 Tel : 81-3-6228-0445
 Fax : 81-3-6228-0486

Visit our webpage



DIT webpage



NCGM webpage

